XNAS
ATHE
Market cap64mUSD
Sep 17, Last price
3.75USD
1D
-2.60%
1Q
-23.16%
Jan 2017
-76.99%
IPO
-99.45%
Name
Alterity Therapeutics Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
44.05%
Rev. gr., 5y
105.93%
Revenues
0
-100.00%
Net income
-23m
L+88.43%
CFO
-22m
L+92.39%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Key people
Executive Chairman of the Board, Chief Executive Officer · since 2005
Kathryn Andrews
Chief Financial Officer · since 2014
David Stamler
Chief Medical Officer and Senior Vice President Clinical Development · since 2017
Tristan Edwards
Non-Executive Director · since 2019
Ira Shoulson
Non-Executive Independent Director · since 2014
David Sinclair
Non-Executive Director · since 2019
Lawrence Gozlan
Non-Executive Independent Director · since 2011
Non-Executive Independent Director · since 2005
Brian Derek Meltzer
Non-Executive Independent Director · since 1999
Legal address
Level 3, 62 Lygon Street
Carlton 3054
AU
Carlton 3054
AU
Headquarters
Level 3, 460 Bourke Street
Melbourne 3000
AU
Melbourne 3000
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||